Xtant Medical Holdings, Inc. (XTNT)
NYSEAMERICAN: XTNT · Real-Time Price · USD
0.380
+0.022 (6.06%)
At close: Dec 20, 2024, 2:32 PM
0.360
-0.020 (-5.26%)
After-hours: Dec 20, 2024, 4:07 PM EST
Xtant Medical Holdings Revenue
Xtant Medical Holdings had revenue of $27.94M in the quarter ending September 30, 2024, with 11.66% growth. This brings the company's revenue in the last twelve months to $113.86M, up 45.11% year-over-year. In the year 2023, Xtant Medical Holdings had annual revenue of $91.30M with 57.50% growth.
Revenue (ttm)
$113.86M
Revenue Growth
+45.11%
P/S Ratio
0.42
Revenue / Employee
$529,591
Employees
215
Market Cap
50.04M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 91.30M | 33.33M | 57.50% |
Dec 31, 2022 | 57.97M | 2.71M | 4.90% |
Dec 31, 2021 | 55.26M | 1.93M | 3.61% |
Dec 31, 2020 | 53.34M | -11.35M | -17.54% |
Dec 31, 2019 | 64.68M | -7.52M | -10.42% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Spero Therapeutics | 106.46M |
SHL Telemedicine | 55.94M |
Celularity | 48.20M |
Cytosorbents | 37.74M |
Dyadic International | 3.36M |
Singular Genomics Systems | 2.67M |
Exicure | 500.00K |
XTNT News
- 5 weeks ago - Xtant Medical Holdings, Inc. (XTNT) Q3 2024 Earnings Conference Call Transcript - Seeking Alpha
- 5 weeks ago - Xtant Medical Reports Third Quarter 2024 Financial Results - Accesswire
- 5 weeks ago - Xtant Medical to Attend the 15th Annual Craig-Hallum Alpha Select Conference - Accesswire
- 6 weeks ago - Xtant Medical to Issue Third Quarter 2024 Financial Results on November 12, 2024 - Accesswire
- 3 months ago - Xtant Medical Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System - Accesswire
- 3 months ago - Xtant Medical Expands Product Portfolio with Launch of its own Viable Bone Matrix, OsteoVive(R) Plus - Accesswire
- 4 months ago - Xtant Medical Holdings, Inc. (XTNT) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Xtant Medical Announces Closing of $5.0 Million Private Placement - Accesswire